Beyond the weight-loss trend: Lower-cost semaglutide is coming to South Africa

Beyond the weight-loss trend: Lower-cost semaglutide is coming to South Africa Novo Nordisk South Africa announced on July 27 that it will begin selling an authorised, more affordable version of semaglutide, the drug behind the popular weight-loss injectable Ozempic. The new product, developed in partnership with Acino, part of Arcera, will be available starting that date. This initiative aims to improve access to treatment for individuals living with type 2 diabetes, rather than being solely driven by the current weight-loss craze. Semaglutide, originally developed based on research into the venom of the Gila monster, a slow-moving desert lizard, has been transformed into a key medication for managing blood sugar levels. Scientists discovered that a specific peptide in the lizard’s venom could mimic human gut hormones, helping regulate digestion and satiety. This discovery led to the creation of semaglutide, which is now used globally for both diabetes management and weight control. In South Africa, the drug is registered by the South African Health Products Regulatory Authority (SAHPRA). According to information released by the companies, the new semaglutide product uses the same active pharmaceutical ingredient, manufacturing process, and administration device as the original. It is not a generic substitute or an unregulated counterfeit. Instead, it is an authorised copy produced under the supervision of the original manufacturer, ensuring consistency in quality and effectiveness. This distinction is crucial, as SAHPRA has repeatedly cautioned the public about the dangers of purchasing unverified GLP-1 medications through informal channels. The demand for semaglutide and similar GLP-1 drugs has surged, particularly due to their role in weight management. However, access to these treatments has remained limited, with affordability and availability posing major challenges. While the drug is primarily approved for treating type 2 diabetes and reducing cardiovascular risk, its popularity as a weight-loss option has amplified its visibility. Over 2.3 million South African adults, roughly 7.2% of the population, live with type 2 diabetes, making this a pressing public health issue. SAHPRA has taken steps to combat the proliferation of unsafe and unapproved GLP-1 products. These include enforcing actions against illegal manufacturers and distributors who sell unregistered medicines, often marketed for weight loss. Products purchased outside the official supply chain may lack the correct dosage of active ingredients, contain harmful substances, or fail to meet basic safety standards. This underscores the importance of relying on authorised copies to ensure patient safety. Sara Norcross, general manager of Novo Nordisk South Africa, highlighted the significance of the new launch. She stated that the company is committed to increasing access to essential treatments for serious chronic conditions. Similarly, John Norman, regional managing director of Acino Africa, emphasized the alignment of the partnership with Novo Nordisk’s mission to enhance patient care. The collaboration represents a strategic effort to address healthcare disparities and provide reliable, cost-effective options for those in need. As the new semaglutide becomes available, it marks a step forward in addressing the challenges surrounding diabetes management and medication accessibility. With proper regulation and awareness, the introduction of this affordable option could lead to improved outcomes for millions of South Africans affected by type 2 diabetes.